# US 2010/0166734 A1 · Oral delivery of polypeptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0166734 A1
- Document ID: US20100166734A1
- Status: Published application
- Kind: A1
- Application number: 12/520,272
- Filed: 2001-12-20
- Published: 2010-07-01
- Earliest claimed: 2001-12-20
- Inventors: Edward Dolk
- Web page: https://patentgrep.com/patent/US20100166734A1

## CPC

- C07K 16/283: {against Fc-receptors, e.g. CD16, CD32, CD64 (CD23 C07K16/2851)}
- A61P 37/00: Drugs for immunological or allergic disorders
- C07K 16/18: against material from animals or humans
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- C07K 16/2869: {against hormone receptors (for antibodies against neuromediator receptors C07K16/286)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/505: {comprising antibodies}
- C07K 2317/22: from camelids, e.g. camel, llama or dromedary
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to the oral delivery of therapeutic polypeptides comprising one or more single variable domain(s).

## Claims

### Claim 1

A pharmaceutical composition for oral administration comprising a therapeutically effective amount of a polypeptide comprising one or more single variable domain(s) and a pharmaceutically acceptable enteric coating.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the polypeptide comprises 2 single variable domains.

### Claim 3 (depends on 2)

The composition of claim 2, wherein the single variable domains are 2 identical Nanobodies.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the polypeptide has agonistic properties.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the polypeptide also comprises a single variable domain against FcRn, pIgR or Vit B12 receptor.

### Claim 6 (depends on 5)

The composition of claim 5 wherein the binding of the single variable domain against FcRn, pIgR or Vit B12 receptor is pH dependent.

### Claim 7 (depends on 1)

The composition of claim 1 additionally comprising a permeability enhancer.

### Claim 8 (depends on 1)

The composition of claim 1 additionally comprising a protease inhibitor.
